Details for Patent: 12,097,285
✉ Email this page to a colleague
Which drugs does patent 12,097,285 protect, and when does it expire?
Patent 12,097,285 protects MYHIBBIN and is included in one NDA.
This patent has four patent family members in three countries.
Drugs Protected by US Patent 12,097,285
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Azurity | MYHIBBIN | mycophenolate mofetil | SUSPENSION;ORAL | 216482-001 | May 1, 2024 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | PROPHYLAXIS OF ORGAN REJECTION | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,097,285
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
European Patent Office | 3836898 | ⤷ Subscribe | |||
United Kingdom | 202103764 | ⤷ Subscribe | |||
United Kingdom | 2591396 | ⤷ Subscribe | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |